Article metrics

Download PDFPDF

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to January 2024

AbstractFullPdf
Nov 2020203023
Dec 20204209
Jan 20214403
Feb 20217408
Mar 202176010
Apr 202186026
May 202131026
Jun 20210010
Jul 20210012
Aug 2021003
Sep 20210016
Oct 202146020
Nov 202176017
Dec 20216806
Jan 20228009
Feb 202258011
Mar 20225806
Apr 2022116010
May 2022104014
Jun 2022134017
Jul 202280012
Aug 20224806
Sep 20224005
Oct 20225606
Nov 202282012
Dec 20224004
Jan 20236402
Feb 20238806
Mar 202388014
Apr 2023105016
May 202314407
Jun 20237407
Jul 20237609
Aug 202380010
Sep 20233602
Oct 202390013
Nov 20239204
Dec 20237405
Jan 20241000
Total26630396